Home › Funds › Livforsakringsbolaget Skandia, Omsesidigt › HALO

Livforsakringsbolaget Skandia, Omsesidigt position in HALO

HALOZYME THERAPEUTICS INC · Health Care

Livforsakringsbolaget Skandia, Omsesidigt reported holding 139,400 shares of HALO (HALOZYME THERAPEUTICS INC) in its Q3 2026 13F filing — a position valued at US$15.4M, representing 0.51% of its reported portfolio and ranking #44 among its reported holdings. Livforsakringsbolaget Skandia, Omsesidigt has disclosed HALO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

Latest position (Q3 2026)139.40K sh
Reported value held$15.39M
Portfolio Weight0.51%
First reportedQ4 2023
Last changeAdd
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How Livforsakringsbolaget Skandia, Omsesidigt's HALO position evolved

Livforsakringsbolaget Skandia, Omsesidigt first disclosed a stake in HALO in Q4 2023 at 5,300 shares (US$196K). The position peaked in Q3 2026 at 139,400 shares, worth US$15.4M. Across 12 filings, Livforsakringsbolaget Skandia, Omsesidigt increased the stake 7 time(s), trimmed it 0 time(s) and left it unchanged 4 time(s). The most recent filing (Q3 2026) shows 139,400 shares valued at US$15.4M — an increase of 15,300 shares quarter over quarter.. Notable position changes include a 770% increase in Q2 2024 (shares rose 9% over the following quarter), a 78% increase in Q2 2025 (shares rose 41% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q4 2023 5.30K $195.89K New
Q1 2024 5.30K $215.34K Hold
Q2 2024 46.10K $2.41M Add
Q3 2024 57.30K $3.28M Add
Q4 2024 57.30K $2.74M Hold
Q1 2025 57.30K $3.65M Hold
Q2 2025 102.00K $5.31M Add
Q3 2025 104.90K $7.69M Add
Q4 2025 104.90K $7.06M Hold
Q1 2026 116.10K $7.50M Add
Q2 2026 124.10K $9.71M Add
Q3 2026 139.40K $15.39M Add

Dots on the line are colored by change type; missing quarters mean no position was reported.

About HALO and 13F data

HALO (HALOZYME THERAPEUTICS INC) is a Health Care company. 45 other funds we track also report a position in HALO — the largest reported positions include CONGRESS ASSET MANAGEMENT CO (US$251.9M), SNYDER CAPITAL MANAGEMENT L P (US$187.5M), WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC (US$178.5M). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding HALO

All HALO fund holders →

FAQ

How long has Livforsakringsbolaget Skandia, Omsesidigt held HALO?

Livforsakringsbolaget Skandia, Omsesidigt has disclosed HALO holdings in 12 of the last 12 reported quarters, going back to Q4 2023.

What is Livforsakringsbolaget Skandia, Omsesidigt's current position in HALO?

As of Q3 2026, Livforsakringsbolaget Skandia, Omsesidigt holds 139.40K shares of HALO (HALOZYME THERAPEUTICS INC), valued at $15.39M, representing 0.51% of its reported portfolio and ranking #44.

Has Livforsakringsbolaget Skandia, Omsesidigt been buying or selling HALO?

In the latest 13F filing (Q3 2026), Livforsakringsbolaget Skandia, Omsesidigt increased its position in HALO. The position peaked in Q3 2026 at 139.40K shares.

Which other funds hold HALO?

Other major institutional holders of HALO include CONGRESS ASSET MANAGEMENT CO, SNYDER CAPITAL MANAGEMENT L P, WILLIAM BLAIR INVESTMENT MANAGEMENT, LLC, among 45 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.